These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37142449)

  • 41. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2018 Aug; 36(8):1622-1636. PubMed ID: 29847485
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation.
    Soliman EZ; Rahman AF; Zhang ZM; Rodriguez CJ; Chang TI; Bates JT; Ghazi L; Blackshear JL; Chonchol M; Fine LJ; Ambrosius WT; Lewis CE
    Hypertension; 2020 Jun; 75(6):1491-1496. PubMed ID: 32362229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials.
    Ploumen EH; Pinxterhuis TH; Zocca P; Roguin A; Anthonio RL; Schotborgh CE; Benit E; Aminian A; Danse PW; Doggen CJM; von Birgelen C; Kok MM
    Cardiovasc Diabetol; 2021 Oct; 20(1):217. PubMed ID: 34717627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Wang KM; Stedman MR; Chertow GM; Chang TI
    Hypertension; 2020 Dec; 76(6):1725-1733. PubMed ID: 33131314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
    Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial.
    Berry JD; Nambi V; Ambrosius WT; Chen H; Killeen AA; Taylor A; Toto RD; Soliman EZ; McEvoy JW; Pandey A; Joshi PH; Blankenberg S; Kitzman DW; Ballantyne CM; de Lemos JA
    JAMA Cardiol; 2021 Dec; 6(12):1397-1405. PubMed ID: 34468696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial.
    Beddhu S; Rocco MV; Toto R; Craven TE; Greene T; Bhatt U; Cheung AK; Cohen D; Freedman BI; Hawfield AT; Killeen AA; Kimmel PL; Lash J; Papademetriou V; Rahman M; Rastogi A; Servilla K; Townsend RR; Wall B; Whelton PK;
    Ann Intern Med; 2017 Sep; 167(6):375-383. PubMed ID: 28869987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial.
    Dolui S; Detre JA; Gaussoin SA; Herrick JS; Wang DJJ; Tamura MK; Cho ME; Haley WE; Launer LJ; Punzi HA; Rastogi A; Still CH; Weiner DE; Wright JT; Williamson JD; Wright CB; Bryan RN; Bress AP; Pajewski NM; Nasrallah IM
    JAMA Neurol; 2022 Apr; 79(4):380-389. PubMed ID: 35254390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort.
    Wokhlu A; Smith SM; Gong Y; Handberg EM; Elgendy IY; Bavry AA; Cooper-DeHoff RM; Pepine CJ
    J Hypertens; 2018 Feb; 36(2):419-427. PubMed ID: 28938338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus.
    Ó Hartaigh B; Szymonifka J; Okin PM
    J Hypertens; 2018 Jan; 36(1):101-109. PubMed ID: 28832365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes.
    Chen CL; Liu L; Huang JY; Yu YL; Lo K; Huang YQ; Feng YQ
    Diabetes Metab Syndr Obes; 2020; 13():2375-2388. PubMed ID: 32753922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial.
    Chen LY; Bigger JT; Hickey KT; Chen H; Lopez-Jimenez C; Banerji MA; Evans G; Fleg JL; Papademetriou V; Thomas A; Woo V; Seaquist ER; Soliman EZ
    Am J Hypertens; 2016 Nov; 29(11):1276-1282. PubMed ID: 26476086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of Blood Pressure and Glycemic Status in Developing Cardiovascular Disease: Analysis of a Nationwide Real-World Database.
    Suzuki Y; Kaneko H; Yano Y; Okada A; Itoh H; Matsuoka S; Yokota I; Imaizumi T; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Yasunaga H; Komuro I
    J Am Heart Assoc; 2023 Jan; 12(1):e026192. PubMed ID: 36565182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 Nov; 35(11):2138-2149. PubMed ID: 28858983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2014 Dec; 32(12):2285-95. PubMed ID: 25255397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT.
    Berry JD; Chen H; Nambi V; Ambrosius WT; Ascher SB; Shlipak MG; Ix JH; Gupta R; Killeen A; Toto RD; Kitzman DW; Ballantyne CM; de Lemos JA
    Circulation; 2023 Jan; 147(4):310-323. PubMed ID: 36533535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systolic blood pressure trajectory and cardiovascular outcomes: An analysis using data in the Systolic Blood Pressure Intervention Trial.
    Lee CL; Wang JS
    Int J Clin Pract; 2020 Mar; 74(3):e13450. PubMed ID: 31755625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
    Attar A; Nouri F; Borazjani R; Sayadi M
    PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.